CrossrefCard informativ
Apremilast for the treatment of psoriasis and psoriatic arthritis
Future Prescriber · 2013
DOI: 10.1002/fps.102 ↗Rezumat
Abstract Apremilast, an orally active inhibitor of phosphodiesterase 4 that inhibits several inflammatory cytokines, is being developed for the treatment of psoriasis and psoriatic arthritis. This Drug profile reviews the clinical data to date. Copyright © 2013 John Wiley & Sons, Ltd.
EUVIMED